Craniosynostosis, Fibroblast Growth Factor Receptors and Gastrointestinal Malformations – A Possible Link
by
Christine Elizabeth Hibberd
A thesis submitted in conformity with the requirements for the degree of Masters of Science
Graduate Department of Dentistry University of Toronto
© Copyright by Christine E Hibberd 2014
ii
Craniosynostosis, Fibroblast Growth Factor Receptors and
Gastrointestinal Malformations – A Possible Link
Christine Elizabeth Hibberd
Masters of Science
Graduate Department of Dentistry University of Toronto
2014
Abstract
Syndromic craniosynostosis is most commonly associated with mutations in Fibroblast Growth
Factor Receptor genes (FGFR)-1, 2 and 3. Clinical and animal reports suggest a link between
FGFR-associated craniosynostosis and defects in the gastrointestinal tract (GIT).
Objective: to determine whether GIT malformations occur more frequently in the
craniosynostosis population with a known FGFR mutation when compared to the general
population.
Methods: A retrospective chart review of patients diagnosed with Crouzon, Pfeiffer or Apert
syndromes between 1990 and 2011 was performed at the Hospital for Sick Children in Toronto.
Thirty-two charts meeting inclusion criteria were analyzed for any history of GIT abnormalities.
Results: Three out of 32 patients had documented intestinal/bowel malrotations while 7 had
gastroesophageal reflux disease. All patients had documented FGFR2 mutations, a finding in line
with previous studies and published case reports.
Conclusions: Results suggest an association between FGFR-associated craniosynostosis and
GIT malformations.
iii
Acknowledgments
There are many people who offered their endless support throughout this process, whom I am
incredibly grateful to.
To Dr. Sarah Bowdin, thank you for your mentorship, encouragement, guidance and
patience over the past three years. I appreciate your vast knowledge in the field of genetics and
craniofacial anomalies that inspires me to become involved in treating patients with craniofacial
differences. It was an absolute pleasure to work with you.
To Dr. Siew-Ging Gong, thank you for your all of your advice and guidance throughout
this project. You have taught me to truly appreciate the importance of basic science in the
context of a very clinical world.
To Dr. Bryan Tompson, thank you for all of your support as the Head of the Department
of Orthodontics and member of my research advisory committee. I will always be grateful for all
you have taught me over the past three years
To Dr. Christopher Forrest, thank you for taking the time out of your busy schedule to
serve on my committee. Your expertise is invaluable and very much appreciated.
To my classmates and friends, Dr. Sean Chung, Dr. Heather Ford and Dr. Marc
Yarascavitch, my sincerest thanks for all of your support, suggestions, advice and
encouragement. The past three years would not have been the same without you.
A very special thank you to my family. To my parents, Graeme and Elizabeth and my
sister Jennifer, thank you for all your support and the endless hours you spent watching Jack and
recently, Henry, in order to make it possible for me to complete my orthodontic program and
thesis. To my adorable sons Jack and Henry, you brighten everyday of my life with love and
excitement. Thank you for being the sweetest boys and making me the happiest mommy in the
world. I love you both so much. And finally to husband and best friend, Andrei, thank you for
your love, continual support, patience and constant encouragement that made it possible for me
to realize and fulfill my dreams. Words cannot describe how much you mean to me and how
much I appreciate all you do. I am very lucky to have you. I love you. I dedicate this thesis to my
loving and supportive family.
iv
TABLE OF CONTENTS
Abstract ii
Acknowledgements iii
List of Tables vii
List of Figures viii
List of Abbreviations ix
I. INTRODUCTION AND LITERATURE REVIEW 1
1. CRANIOSYNOSTOSIS 1
1.1. Cranial sutures – development and fusion: 1
1.2. Craniosynostosis terminology 3
Simple/complex and primary/secondary synostosis 4
Syndromic craniosynostosis 4
1.3 Incidence 6
1.4 Management 6
1.5 Causes 7
1.6 Genetic overview of craniosynostosis syndromes 7
2. FIBROBLAST GROWTH FACTOR (FGF) RECEPTORS 9
2.1 Structure 9
2.2 Evolution 9
2.3 Biological roles 10
v
2.4 Mutations of FGFRs in craniosynostosis syndromes 10
2.5 Genotype-phenotype correlations 11
3. GASTROINTESTINAL TRACT (GIT) 16
3.1 Gastrointestinal development and FGF signalling 16
3.2 GI malformations 17
EUROCAT classification system 17
Intestinal malrotation 19
Gastroesophageal Reflux Disease (GERD) 19
3.3 Craniosynostosis and structural/functional anomalies of the GI system 20
II. HYPOTHESIS AND OBJECTIVES 22
III. MATERIALS AND METHODS 23
IV. RESULTS 25
1. Patient sample: 25
2. Craniosynostosis syndromes and mutations: 25
3. GIT anomalies 28
4. Summary 30
V. DISCUSSION 31
1. Genetic findings in sample population 31
2. Intestinal malrotation in sample population 32
3. Proposed mechanism 34
vi
4. Study limitations 35
VI. FUTURE DIRECTIONS 37
VII. CONCLUSION 38
VIII. REFERENCES 39
IX. APPENDICES
Appendix A: The Hospital for Sick Children Research Ethics Board Approval 52
Appendix B: The Hospital for Sick Children Research Ethics Board Reapproval 54
vii
List of Tables
Table 1: FGFR mutations and associated disorders.
Table 2: EUROCAT category and description of gastrointestinal anomaly.
Table 3: Number and type of mutations identified in a sample of 32 FGFR-associated
craniosynostosis syndromic patients at SickKids (Toronto, Ontario) between the years of 1990-
2011.
Table 4: Observed Fibroblast Growth Factor Receptor mutations and associated findings.
Table 5: Frequency of Intestinal/Bowel Malrotation and GERD in the sample population of CS,
PS and AS patients.
viii
List of Figures
Figure 1: Major bones and sutures of the adult human cranium.
Figure 2: Distribution of germline mutations in FGFR1, FGFR2 and FGFR3 causing missense
substitutions or probable splicing abnormalities.
Figure 3: Distribution and types of mutations observed in the sample population of CS, PS and
AS patients (pictured above FGFR2 protein).
ix
List of Abbreviations
Apert syndrome AS
Arginine Arg
Base pairs bp
Central nervous system CNS
Cleft palate CP
Crouzon syndrome CS
Crouzon syndrome with acanthosis nigricans CS-AN
Cysteine Cys
Extracellular signal-regulated kinases ERKs
European Surveillance of Congenital Anomalies EUROCAT
Fibroblast Growth Factor FGF
Fibroblast Growth Factor Receptor FGFR
Gastroesophogeal reflux disease GERD
Gastrointestinal GI
Gastrointestinal tract GIT
Heparan sulfate proteoglycan HSPG
Hospital for Sick Children SickKids
Immunoglobulin Ig
Left-right L/R
Mitogen-activated protein MAP
Pfeiffer syndrome PS
Phenylalanine Phe
x
Proline Pro
Protein kinase C PKC
Transforming growth factor TGF-β
Tyrosine Tyr
Tyrosine kinase TK
Serine Ser
1
I. INTRODUCTION AND LITERATURE REVIEW
Craniosynostosis is a condition characterized by the premature fusion of one or more
cranial sutures. Craniosynostosis may be isolated or as part of multisystem syndromes. When a
child is suspected to have a craniosynostosis syndrome they may require further diagnostic and
genetic tests as these individuals often have a higher risk of other physical and developmental
conditions. The genetic cause of syndromic craniosynostosis is heterogeneous; however, the
most commonly mutated genes are the Fibroblast Growth Factor Receptor (FGFR) genes,
specifically FGFR1, FGFR2 and FGFR3.
Several published reports present gastrointestinal (GI) malformations, in particular
intestinal malrotations, as comorbidities associated with syndromic craniosynostosis. These
reports, along with evidence from mouse models, suggest an association. Expression of the
FGFRs in the GI tract (GIT) further strengthens a possible genetic link between FGFR-
associated craniosynostosis syndromes and the presence of GI defects in these patients. This
study is focused on analyzing the incidence of specific GI defects in craniosynostosis patients
with known mutations in the FGFR genes. This section will begin with a brief review of the
formation of cranial sutures, followed by the incidence, types, causes, and management of
craniosynostosis and a discussion of the associated syndromes. The genetic basis of FGFR-
associated craniosynostosis and the related GIT changes will be discussed in the following
sections.
1. CRANIOSYNOSTOSIS
1.1 Cranial sutures – development and fusion:
The neurocranium is composed of flat calvarial bones and a cranial base (Fig.1).
Intramembranous bone formation is responsible for generating the flat calvarial bones that give
rise to the roof and sides of the skull whereas the cranial base develops by endochondral bone
formation. Needle-like bone spicules radiate peripherally at the margins of the frontal, parietal
and occipital bones to produce the fontanelles and sutures (Cohen, 2002). Fontanelles are soft
membranous gaps found between incompletely formed cranial bones on an infant’s skull.
2
Sutures develop at the periphery of the extending bone fields, due to a wedge-shaped
proliferation of cells, referred to as osteogenic fronts (Decker & Hall, 1985). It is these
osteogenic fronts that seem to direct the morphogenetic determination of sutural patterning. The
osteogenic fronts can approach each other in one of two ways, yielding either an edge-to-edge
suture or a beveled suture (Johansen & Hall, 1982). End-to-end sutures form in the midline of the
skull with both the sagittal and metopic sutures being formed this way (Kokich, 1976). Coronal,
lambdoidal and frontozygomatic sutures are formed away from the midline and form a beveled
suture (Cohen, 2002). It has been proposed that the end-to-end suture is the result of
biomechanical forces equal in magnitude acting on each opposing side of the midline and
initiating suture formation while maintaining the flat calvarial bones in the same plane of space
(Cohen, 2002). In contrast, sutures formed away from the midline are likely to be affected by
unequal biomechanical forces, thus moving the bones into different planes of space yielding an
overlapping, beveled suture (Cohen, 2002). Fusion of the sutures located along the cranial
midline, such as the sagittal and metopic sutures, seem to produce more prominent ridging
compared to the ridging observed with synostosis of the sutures occurring away from the midline
such as the coronal and lambdoidal sutures (Cohen, 2002).
The timing of fusion of these sutures follows a strict temporal pattern, with most of the
sutures normally fusing after birth. In infancy, flexible sutures and open fontanelles allow for
deformation of the calvarium by enabling the bones of the skull to overlap as an infant passes
through the birth canal during delivery without damaging the infant’s brain (Levi et al., 2012).
During childhood, the brain grows and expands rapidly. Patent sutures allow the brain to grow
quickly without being constricted, while still providing a protective shell for the brain. The
fontanelles are the first to close during infancy and early childhood, followed by sutural fusion in
early adulthood when growth is complete (Cohen, 2002). The closure of the posterior fontanelle
generally occurs by the third month of life, while the anterior fontanelle typically closes between
the ages of 7-19 months (Aisenson, 1950). The metopic suture is the only suture that fuses early
on in life, undergoing fusion between six to eight months of age (Weinzweig et al., 2003). All
other cranial sutures usually begin to close when an individual enters his/her early twenties,
commencing most often with the sagittal suture. Fusion of the coronal suture closure occurs in
the mid-twenties and lastly the lambdoid suture in the late twenties (Morriss-Kay & Wilkie,
3
2005). Thus, a failure in this sequencing resulting in the premature fusion of one or more of
these sutures causes a birth defect known as craniosynostosis.
Figure 1: Major bones and sutures of the adult human cranium. Lateral (left) and top (right)
view demonstrating the bones (red line) and sutures (blue) of the calvarium. The metopic suture
separating the right and left halves of the frontal bone generally closes by the second year of
life.
Reprinted with permission from Levi et al., 2012
1.2 Craniosynostosis terminology
Craniosynostosis is recognized clinically and radiographically as the premature fusion of one or
more cranial sutures. It is the most common congenital defect of the human skull (Cohen, 1988;
Robin et al., 2011). To aid in diagnosis and treatment, different classification systems are
employed to describe the specific type of craniosynostosis. Classification is based upon the
number of sutures involved, their anatomical locations, shape of the head, etiology, and whether
the synostosis is an isolated physical difference or part of a syndrome.
4
Simple/complex and primary/secondary synostosis
Simple craniosynostosis is a term used to describe the premature fusion when only one
suture fuses prematurely. When multiple sutures are involved, this is termed complex or
compound craniosynostosis (Kimonis et al., 2007).
Primary synostosis results from a defect of ossification and may involve a single or
multiple sutures, for example coronal synostosis only or coronal and sagittal synostosis (Cohen,
2002). It is believed that this premature fusion is the direct result of a developmental error during
embryogenesis (Nagaraja et al., 2013). Secondary craniosynostosis is caused as a result of
another medical condition or environmental issue, which subsequently impedes normal suture
formation (Cohen, 2002; Kimonis et al., 2007). Numerous conditions are associated with
secondary craniosynostosis, including metabolic disorders, hematological disorders and
teratogens (Cohen & MacLean, 2000).
Syndromic craniosynostosis
When craniosynostosis is accompanied by other physical or developmental anomalies it
is designated as syndromic craniosynostosis (Kimonis et al., 2007). All craniosynostosis
syndromes have defects in common with each other as a result of the premature fusion of the
cranial sutures. The shape of the skull is distorted due to the inability of growth to occur
perpendicularly to the prematurely fused suture and the resultant supplementary overgrowth at
the non-fused sutures of the cranium. In addition to craniosynostosis, several defects occur in the
midfacial region such as midfacial hypoplasia, exophthalmos, dental problems, and orofacial
clefting.
More than one hundred syndromes have been described in which craniosynostosis is a
documented feature (Cohen, 2002; Cornejo-Roldan et al., 1999; Robin et al., 2011). Examples
of craniosynostosis syndromes include Crouzon, Pfeiffer and Apert syndrome. These syndromes
share characteristics such as midface hypoplasia, hypertelorism, exophthalmos, a hypoplastic
maxilla and relative mandibular prognathism. Although similar in many respects, each syndrome
differs, in particular in the extent of involvement of the limbs and the associated abnormalities
that are observed in both Pfeiffer and Apert syndrome. Crouzon syndrome (CS) is the most
common syndrome of the three and is generally the most mild in presentation with individuals
5
often having normal or near normal intelligence (Forrest & Hopper, 2013). CS is characterized
by the absence of limb defects, in contrast to Pfeiffer and Apert syndromes (Johnson & Wilkie,
2011)
Pfeiffer syndrome (PS) is characterized by craniosynostosis of variable degrees, with
distinct phenotypic features that include midface hypoplasia, severe exophthalmos, ocular
hypertelorism, psittichorhina, broad radially deviated thumbs and toes, and in some cases partial
cutaneous syndactyly of the hands and feet (Johnson & Wilkie, 2011; Lajeunie et al., 2006).
Recognized central nervous system (CNS) malformations in PS include hydrocephalus and
congenital or acquired Chiari malformation (Kabbani & Raghuveer, 2004; Ranger et al., 2010).
Other recognized associations are radio-ulnar synostosis, and fusion of the cartilaginous tracheal
rings (Akai et al., 2006; C.-P. Chen et al., 2008; Gonzales et al., 2005; Hockstein et al., 2004;
Lajeunie et al., 2006; Oliveira et al., 2006; Ranger et al., 2010; Stevens & Roeder, 2006; Zackai
et al., 2003). These severely affected patients frequently have a high mortality rate in infancy or
early childhood (Akai et al., 2006; Lajeunie et al., 2006). PS is subdivided into three clinical
types, 1, 2 and 3. Type 1 is a milder form of PS whereas both type 2 and 3 exhibit severe
phenotypic expression. PS type 1 characteristics include craniosynostosis, broad thumbs and
toes, and partial syndactyly of the hands and feet to varying degrees (Barone et al., 1993;
Johnson & Wilkie, 2011; Koga et al., 2012). These individuals have normal or near normal
intelligence (Barone et al., 1993). PS type 2 characteristics include craniosynostosis manifesting
as a cloverleaf skull, broad thumbs and toes, severe ocular proptosis and central nervous system
malformations. These individuals can also be affected with elbow ankylosis or synostosis and
other anomalies (Barone et al., 1993). PS type 3 is very similar to type 2, but is differentiated by
the lack of the cloverleaf skull. Further characteristics include shallow orbits, and a
foreshortened anterior cranial base (Barone et al., 1993). Limb defects found in PS involves the
broadening of the thumbs and/or big toes and may exhibit either unilateral or bilateral
involvement. Some cases may also involve cutaneous syndactyly (Lajeunie et al., 2006). The
severity and extent of involvement of the limbs is a useful diagnostic aid to distinguish between
PS and Apert syndromes.
Apert syndrome (AS) is characterized by bicoronal craniosynostosis, midface hypoplasia
and severe bilateral and symmetrical syndactyly of the hands and feet (Johnson & Wilkie, 2011;
Kaplan, 1991; Wilkie et al., 1995). Another finding frequently found associated with AS is a
6
cleft palate (Johnson & Wilkie, 2011). Individuals with AS also have a high risk of learning
impairments and disability (Johnson & Wilkie, 2011). The extent of the involvement and
symmetry in the malformations of the hands and feet in AS distinguishes this syndrome from PS.
1.3 Incidence
The overall incidence of craniosynostosis has been estimated to range between 1:2100 to
1:3000 live births (Lajeunie et al., 1995). It has been estimated that approximately 85% of
documented cases are isolated, involving only a single suture, with the remaining 15% of cases
being syndromic (Chumas et al., 1997). The incidence of syndromic craniosynostosis is reported
to be between one in 25,000 and one in 100,000 infants (Forrest et al., 2013).
The location of the synostosis, ranked from most to least commonly observed are the
sagittal, coronal (either unilaterally or bilaterally), metopic, and then lambdoidal sutures (Cohen
& MacLean, 2000; Johnson & Wilkie, 2011). Sagittal synostosis accounts for approximately 40-
55% of non-syndromic synostotic cases, with coronal synostosis accounting for 20-25%, metopic
synostosis accounting for 10-15% and finally lambdoidal synostosis occurring rarely up to 5%
(Slater et al., 2008). Recent reports suggest that the involvement of the metopic suture may be
more prevalent than previously reported (Forrest & Hopper, 2013). These studies indicate that
metopic synostosis is found to in one in 10,000 live births compared to coronal synostosis
occurring in one in 15,000 live births (Selber et al., 2008; van der Meulen et al., 2009). In
general, there is a male predominance of the symmetric craniosynostoses (sagittal and metopic)
and a female predominance of the asymmetric subtypes (Forrest & Hopper, 2013).
1.4 Management
The management of individuals with craniosynostosis can range from minimal
involvement to requiring extensive care. Specifically, patients with syndromic craniosynostoses
require complex care which is best approached by a multidisciplinary team to effectively address
the vast array of their needs (Cunningham et al., 2007; Derderian & Seaward, 2012). Patients
often require multiple staged procedures which are carried out throughout childhood and
7
adolescence at age-appropriate intervals (Forrest & Hopper, 2013). As an example, procedures
may involve cranial vault remodeling, cleft repair, tracheostomies or limb reconstruction,
depending upon the presenting problems. A multidisciplinary team should ideally include
genetics, plastic surgery, neurosurgery, neuroradiology, dentistry, orthodontics, oral and
maxillofacial surgery, ophthalmology, otolaryngology, anesthesiology, psychiatry, social work,
occupational therapy, speech and language pathology and nursing in a tertiary care facility with
expertise in this area (Forrest & Hopper, 2013). Expertise is established based upon volumes of
patients and interest in the area (Cunningham et al., 2007).
1.5 Causes
The premature fusion of a suture or sutures may be the result of mechanical pressures,
metabolic, or genetic defects or teratogenic exposure (Nagaraja et al., 2013). Intrauterine
compression of the skull against the maternal pelvis could result in a mechanical cause of
synostosis (Johnson & Wilkie, 2011; Kimonis et al., 2007; Levi et al., 2012; Oliveira et al.,
2006). Hyperthyroidism is an example of a metabolic condition that can induce premature fusion
(Kabbani & Raghuveer, 2004; Nagaraja et al., 2013). Numerous genetic factors have been
implicated in the cause of synostosis. These genes encode proteins that are known to be
involved in the control of intramembranous ossification of the skull (Coussens et al., 2007).
1.6 Genetic overview of craniosynostosis syndromes
The identification of specific genetic mutations, in both syndromic and non-syndromic
cases of craniosynostosis, has led to a greater understanding of the etiology, development and
presentation of these disorders.
In general, evidence supports an autosomal dominant mode of inheritance and it is
believed that approximately 8% of all individuals with craniosynostosis have a dominant family
history of this condition (Cohen, 2002). However, the phenotype is not always consistent among
affected relatives of the same family. While some pedigrees do display fusion of a specific suture
such as coronal, sagittal or metopic, others will exhibit synostosis of different sutures (Cohen,
8
2002). Intrafamilial phenotypic variation can be extensive, leading to significant differences in
management and morbidity.
Over 60 different mutations have been identified to be causal in syndromic forms of
craniosynostosis. The majority of these mutations occur in the FGFR2 gene. As part of a 10-
year prospective cohort study testing 326 affected children, Wilkie and colleagues (2010)
identified FGFR2 as the most frequent mutation (32% of all genetic cases) followed by FGFR3
(25%), TWIST1 (19%) and EFNB1 (7%). Other well established, but considerably rarer,
associated genes include FGFR1 (mild PS), POR (Antley-Bixler syndrome) and RAB23
(Carpenter syndrome). Furthermore, other single-gene defects have been reported and include
mutations in EFNA4 (non-syndromic coronal synostosis), ESCO2 (Roberts syndrome), GLI3
(Greig syndrome), JAG1 (Alagille syndrome), KRAS (Noonan syndrome), RECQL4 (Baller
Gerold syndrome), TGFBR1 or TGFBR2 (Loeys-Dietz syndrome) and MSX2 (Boston type)
(Florisson et al., 2013; Jabs et al., 1993; Johnson & Wilkie, 2011; Merrill et al., 2006; Wilkie et
al., 2010).
9
2. FIBROBLAST GROWTH FACTOR (FGF) RECEPTORS
2.1 Structure
The activities of fibroblast growth factors (FGF) are mediated by four cell surface
tyrosine kinase (TK) receptors, FGFR 1-4 (Ornitz & Marie, 2002). The receptors consist of an
extracellular region, a single hydrophobic membrane-spanning segment and a cytoplasmic TK
domain (Johnson et al, 1991). The extracellular area serves as the ligand recognition and binding
site and it is composed of three immunoglobulin (Ig)-like domains, designated IgI–IgIII, a stretch
of seven to eight acidic residues in the linker connecting IgI and IgII, designated the “acid box”
and a conserved positively charged region in IgII that serves as a binding site for heparin
(Schlessinger et al., 2000). Two highly conserved cysteine residues form an intramolecular
disulfide bridge stabilizing the loop structure of the three Ig-like domains. The cytoplasmic
domain contains the catalytic protein TK core which serves to recruit and activate docking and
signaling proteins (Eswarakumar et al., 2005). Ligand binding to the FGFR in conjunction with
a heparan sulfate proteoglycan (HSPG) causes receptor dimerization, transphosphorylation and
activation of an intracellular TK domain (Jaye, Schlessinger, & Dionne, 1992). The dimeric
FGFR is stabilized by both FGF-mediated interactions, direct receptor–receptor interactions as
well as by binding of the HSPG to the heparin binding domains as well as the FGF molecules
(Schlessinger et al., 2000). Receptor activation leads to the docking of adapter proteins followed
by the activation of a signal transduction cascade that regulates genetic expression causing
diverse biological responses (Szebenyi & Fallon, 1999). Receptors differ from one another
mainly in their ligand affinities and tissue distribution (Burke et al., 1998).
2.2 Evolution
The genes coding for FGFs and their receptors have been identified in multicellular
organisms ranging from the nematode, Caenorhabditis elegans, to the mouse, Mus musculus, and
the human, Homo sapiens. However, they have not been identified in unicellular organisms such
as Escherichia coli and Saccharomyces cerevisiae. Evidence exists indicating that both the FGF
and FGFR gene families have greatly expanded during the evolution of primitive metazoa to
vertebrates. The co-evolution of FGF and FGFR genes has permitted increased ligand-receptor
10
specificity, enabling the formation of preferred ligand-receptor interactions offering this
signaling system a great functional diversity and therefore an almost ubiquitous involvement in
developmental and physiologic processes (Itoh & Ornitz, 2004).
2.3 Biological roles
In recent years, the analysis of FGFR mutations involved in human skeletal disorders and
advances in mouse genetics have revealed essential molecular mechanisms by which FGF/FGFR
signaling controls tissue formation. Reported roles of FGFRs have included regulation of cell
division, cell growth and maturation, formation of blood vessels, wound healing and bone
growth during embryonic development (Hughes, 1997). FGFRs have been intensely studied as a
possible anticancer target for their role in tumour cell proliferation, angiogenesis and migration
(Kumar, Narasu, Gundla, Dayam, & J A R P, 2013) and for their involvement in bone formation
and metabolism (Du et al., 2012).
In the skeleton, FGF/FGFR signaling is an important regulator of prenatal and postnatal
bone development (Marie, 2003; Ornitz & Marie, 2002). During embryonic development, the
FGF/FGFR interaction has been shown to control the switch between adipocyte and osteoblast
differentiation in mesenchymal bone marrow stromal cells (Xiao et al., 2010). Genetic studies in
mice and humans have highlighted the important role of FGFR1/2 signaling in the control of
osteoblast gene expression and bone formation (Wilkie, 2005). FGF2 signaling activates many
internal signaling pathways in osteoblasts, including mitogen-activated protein (MAP),
extracellular signal-regulated kinases (ERKs), p38 MAP kinase and protein kinase C (PKC).
These pathways were known to mediate osteoblast proliferation, expression of specific osteoblast
genes and survival (Marie, 2003)
2.4 Mutations of FGFRs in craniosynostosis syndromes
Mutations of FGFR1-3 have been associated with a variety of phenotypic abnormalities
and often significant phenotypic variability is observed even among familial cases (Passos-
Bueno et al., 1999). Few phenotype-genotype correlations are absolute suggesting that
11
phenotypic features may also be determined by epigenetic factors or unlinked modifier genes
(Robin et al., 2011).
What is known is that the majority of FGFR mutations act in an autosomal dominant
way, are frequently de novo and result in increased activation of the mutant receptor, sometimes
independently of the ligand (Passos-Bueno et al., 1999). This is termed a “gain-of-function”
mutation.
Missense or splice-site mutations account for the majority of all observed nucleotide
changes with the occasional occurrence of small inframe insertions and deletions being
documented in FGFR-associated craniosynostosis syndromes (Cohen, 2002). FGFR mutations
may affect the extracellular or intracellular domains (Cohen & MacLean, 2000). When FGFR
mutations create or destroy cysteine residues, an unpaired cysteine remains that can generate
intermolecular disulfide bonding resulting in constitutive receptor activation (Neilson & Friesel,
1996). These gain of functions mutations cause alterations that can cause varying degrees of
ligand-independent signaling. An FGFR mutation can allow early human development to
proceed normally but may exert its interference with later bone development (Cohen, 2002).
2.5 Genotype-phenotype correlations
Missense mutations in FGFR1-3 have been associated with craniosynostosis and human
chondrodysplasia (Table 1). Typically, these mutations account for eight predominant
syndromes, comprising the FGFR-related craniosynostosis spectrum (Robin et al., 2011). These
include: AS, PS, CS, CS with acanthosis nigricans (CS-AN), Beare-Stevenson syndrome,
FGFR2-relatated isolated coronal synostosis, Jackson-Weiss syndrome and Muenke syndrome.
All of these mutations are autosomal dominant and often arise spontaneously (Ornitz & Marie,
2002).
12
Table 1: FGFR mutations and associated disorders. Gene Characteristic mutation (%
responsible) Disorder
FGFR1 Widespread (haploinsufficiency) P252R (100%) N330I, Y374C, C381R
Kallman syndrome Pfeiffer syndrome (PS) Osteoglophonic dysplasia
FGFR2 S252W (66%), P253R (32%) IgIIIc (71%), IgIIIa (23%), TK, IgI Y375C (>85%), S372C
Apert syndrome (AS) Crouzon(CS)/Pfeiffer(PS)/ Jackson-Weiss/Antley-Bixler syndromes Beare-Stevenson syndrome
FGFR3 P250R (>99%) A391E (100%) G380R (99%) K650M (100%) N540K (42%) R248C (56%), Y373C (22%), stop codon (12%) K650E (100%)
Meunke syndrome Crouzon syndrome with acanthosis nigricans(CS-AN) Achondroplasia Severe achondroplasia with acanthosis nigricans Hypochondroplasia Thanatophoric dysplasia I (TDI) Thanatophoric dysplasia II (TDII)
Adapted with permission from Wilkie, 2005
Three distinct craniosynostosis syndromes (CS, PS and AS) are usually caused by
heterozygous mutations of FGFR2 (Johnson & Wilkie, 2011). The mutations can be widely
distributed across the FGFR2 gene, yet the majority are found in the IgIIIa/IIIc domain. Several
critical mutational “hot spots” have been described in this domain for CS and PS patients in
codons 278, 290 and 342 (Kress et al., 2000; Schaefer et al., 1998). Mutations in these areas can
result in unpaired cysteine residues, ultimately disrupting the protein structure by forming
intermolecular dimerization that leads to constitutive activation of the receptor (Neilson &
Friesel, 1996).
Interestingly, mutations occurring on the same codon can exhibit very different
phenotypes as a result of which nucleotide substitution occurs. For example, two FGFR2
mutations creating cysteine residues (p.Trp290Cys and p.Tyr340Cys) cause severe forms of PS
whereas conversion of the same residues into another amino acid (p.Trp290Gly, p.Trp290Arg,
p.Tyr340His) results exclusively in the CS phenotype (Lajeunie et al., 2006). This suggests that
alteration of the protein may cause a different functionality of the gene itself.
13
Figure 2: Distribution of germline mutations in FGFR1, FGFR2 and FGFR3 causing missense
substitutions (above protein) or probable splicing abnormalities (below protein). The mutation
prevalence is indicated on a logarithmic scale and different phenotypes are color-coded. Where
multiple phenotypes occur with mutation at a single position, the column colors are partitioned
proportionately using a linear scale. Substitutions recorded in more than 20 independent subjects
14
are identified individually. For clarity, insertions, deletions and nonsense mutations (none of
which has occurred as a recurrent mutation) are omitted; ‘‘Antley– Bixler’’ and ‘‘Jackson–
Weiss’’ phenotypes are lumped with Pfeiffer syndrome. Data for FGFR1 and FGFR2 are from
Wilkie’s unpublished database; data for FGFR3 are from Passos-Bueno et al. (1999),
supplemented with additional mutations. In each case the alternatively spliced IIIc spliceform is
shown; no mutations have been described in any of the IIIb exons.
Reprinted with permission from Wilkie, 2005
More than 50 mutations have been described in CS with approximately 95% of them
being located in just two exons of the gene encoding the extracellular IgIII domain, i.e., the IIIa
and IIIc domains (Meyers et al., 1996). Many of these mutations are believed to alter
downstream receptor signaling (Anderson et al., 1998; Ibrahimi et al., 2001; Mangasarian et al.,
1997; Mansukhani et al., 2000; Plotnikov et al., 2000). Mutations causing AS have been shown
to result in the loss of ligand binding specificity and thus can be activated by inappropriate
ligands, whereas CS and PS mutations in FGFR2 result in ligand independent activation and
dramatic decreased ligand binding (Ibrahimi et al., 2001; Mangasarian et al., 1997; Marie et al.,
2012; Plotnikov et al., 2000).
The mutations associated with PS overlap considerably with that of CS. PS type 1 can be
caused by a mutation in FGFR1 or FGFR2 (Koga et al., 2012). PS type 2 and 3 manifest as more
severe forms of the disorder, both occurring as de novo mutations. A small subset of
substitutions in the FGFR2 gene encoding p.Trp290Cys, p.Try340Cys, p.Cys342Arg or
p.Ser351Cys account for a large majority of the severely affected cases (Johnson & Wilkie,
2011).
Over 98% of patients diagnosed with AS have been found to have a missense mutation of
FGFR2 in the linker between the IgII and IgIII domains at codon p.Ser252Trp (66%) or
p.Pro253Arg (32%) (Johnson & Wilkie, 2011). In these cases some phenotypic correlations can
be drawn depending upon the specific mutation. Individuals with the FGFR2 mutation
p.Ser252Trp tend to present more often with cleft palates, severe ocular problems and
nasolacrimal stenosis (Akai et al., 2006). Intellectual disability and syndactyly appears to be
15
more severe in individuals with the with the p.Pro253Arg mutation in the FGFR2 gene (Akai et
al., 2006; Jadico et al., 2006; Johnson & Wilkie, 2011; Slaney et al., 1996).
Mutations in FGFR3 are involved in both craniosynostosis and human
chondrodysplasias. A correlation has been observed between a mutation in FGFR3
(p.Ala391Glu) and the development of acanthosis nigricans (AN) in patients with CS; however,
patients with CS without AN are very unlikely to display this specific mutation (Robin et al.,
2011). Achondroplasia, the most common form of short-limb dwarfism, has been linked to
specific mutations within the transmembrane region of FGFR3 with G380R accounting for
nearly all cases (Rousseau et al., 1996; Shiang et al., 1994; Wilkie, 2005)
16
3. GASTROINTESTINAL TRACT (GIT)
3.1 GI development and FGF signaling
The molecular basis for the development of the GIT is not completely understood.
Morphogens, substances that originate from a localized source and form a concentration gradient
throughout a tissue, are involved in the building of complex organs with intricate patterns of
cellular specialization (Wolpert, 1996). A few highly conserved morphogenetic signaling
pathways have now been identified in the development of the GIT. The four most important
morphogenetic signaling pathways that have been shown to play a role in patterning of the early
gut tube are FGF, Hedgehog, Wnt and Transforming Growth Factor (TGF)-β. These pathways
are conserved among organisms from the fruit fly to the human (Dab et al., 2013; van den Brink,
2007).
At a molecular level, studies have demonstrated that the FGFRs and the FGF ligands are
expressed along the entire GIT and are known to play a critical role in the development of GI
structures and multiple other organ systems. High levels of expression of FGFR2 have been
found throughout the GIT in adult human tissues (Hughes, 1997), specifically throughout the
gastric epithelium and submucosal macro- and microvasculature, with marked expression in the
muscularis mucosae and muscularis. FGFR2 expression is widespread in the entire mucosal
epithelium and muscularis in the entire ileum and appendix, with minimal expression observed in
hepatocytes and bile duct (Hughes, 1997).
Mouse models have been instrumental in uncovering many of the potential abnormalities
of the GIT associated with Fgfr2 mutations. Fairbanks et al., (2004) reported that duodenal
atresia was present with a 35% penetrance in Fgfr2b mutant mice embryos. A CS mouse model
with a specific Fgfr2 mutation (in codon 290 of Fgfr2), a mutation also found in humans with
CS, has been characterized to present with numerous GI defects (Dab et al., 2013; Mai et al.,
2010). The Fgfr2W290R mutants had numerous defective organ formation such as bones, teeth,
glands, and lungs (Mai et al., 2010). Additionally, they also presented with specific histological,
structural and functional defects in the esophagus (Dab et al., 2013). The GIT were much
shorter with a relatively empty peritoneal cavity. The mutant mice exhibited a decreased
thickness in the both the muscle layers and epithelium of the esophagus with a reduction in cell
proliferation noted. The esophageal layers also contained reduced collagen contention in
17
conjunction with a distinct patterning change in the orientation of muscle fibers of these mutant
mice and demonstrated reduced contractile activity compared to wildtype mice (Dab et al.,
2013). The findings in the Fgfr2W290R mutant mice therefore suggest a strong correlation between
the Fgfr mutation and GI malformations. The correlation therefore lends a plausible scientific
explanation for the anecdotal and observed findings of GI problems in Fgfr2 related
craniosynostosis patients, such as CS.
3.2 GI malformations
The GIT system is complex both developmentally and structurally. During embryonic
development, abnormalities of development of the GIT may involve one or multiple areas with
or without involvement of the other systems in the body. Some anomalies are readily detected,
yet others may not initially be apparent.
Common congenital GI malformations found in patients treated at a tertiary/quaternary
care academic hospital, the Hospital for Sick Children (SickKids) in Toronto, Ontario, Canada,
include esophageal atresia with or without tracheo-esophageal fistula, intestinal atresia,
malrotation with volvulus, Hirschsprung's disease, ano-rectal malformations and abdominal wall
defects. These anomalies are often classified using the European Surveillance of Congenital
Anomalies (EUROCAT) system.
EUROCAT classification system
EUROCAT is a network of population-based registries for the epidemiologic surveillance
of congenital anomalies. This database is useful for providing incidence data for rare congenital
anomalies, including those of the digestive system and abdominal wall defects. This registry has
documented 1.7 million births in 21 countries of Europe. (http://www.eurocat-network.eu/).
Categories classified under the EUROCAT heading of Digestive System include:
oesophageal atresia with or without tracheo-oesophageal fistula, duodenal atresia or stenosis,
atresia or stenosis of other parts of small intestine, ano-rectal atresia and stenosis, Hirschsprung’s
disease, atresia of bile ducts, annular pancreas, diaphragmatic hernia. Additional categories to be
reviewed included intestinal malrotation and gastroesophogeal reflux disease (GERD).
18
Categories classified under the EUROCAT heading of abdominal wall defects include
gastroschisis and omphalocele. A description of each anomaly is provided in the Table 2 below.
Table 2: EUROCAT category and description of gastrointestinal anomaly. Digestive system
CATEGORY DESCRIPTION Oesophageal atresia with or without tracheo-oesophageal fistula
Occlusion or narrowing of the oesophagus with or without tracheo-oesophageal fistula
Duodenal atresia or stenosis Occlusion or narrowing of duodenum
Atresia or stenosis of other parts of small intestine
Occlusion or narrowing of other parts of the small intestine
Ano-rectal atresia and stenosis Imperforate anus or absence or narrowing of the communication canal between the rectum and anus with or without fistula to neighbouring organs
Hirschsprung’s disease Absence of the parasympathetic ganglion nerve cells (aganglionosis) of the wall of the colon or rectum. May result in cong. megacolon.
Atresia of bile ducts Congenital absence of the lumen of the extrahepatic bile ducts
Annular pancreas Pancreas surrounds the duodenum causing stenosis
Diaphragmatic hernia Defect in the diaphragm with protrusion of abdominal content into the thoracic cavity. Various degree of lung hypoplasia on the affected side
Abdominal wall defects
CATEGORY DESCRIPTION Gastroschisis Protrusion of abdominal contents through an
abdominal wall defect lateral to an intact umbilical cord and not covered by a membrane
Omphalocele Herniation of abdominal content through the umbilical ring, the contents being covered by a membrane sometimes at the time of delivery.
Source: European Surveillance of Congenital Anomalies (http://www.eurocat-network.eu/)
19
Intestinal malrotation
Intestinal malrotation is a serious and potentially fatal developmental anomaly. Both the
small and large intestines can be affected during development in fetal life involving both the
position and peritoneal attachments leading to malrotation (Cassart et al., 2006). In majority of
cases, diagnosis is made during the first year of life (Pickhardt & Bhalla, 2002). Diagnostic
symptoms include abdominal pain, bile stained vomit secondary to bowel obstruction, bowel
dilatation, ascites or meconium peritonitis (Nehra & Goldstein, 2011). Nevertheless, the true
incidence of intestinal malrotation remains unknown (Nehra & Goldstein, 2011). The literature
cites incidences ranging from 1:200 to 1:6000, with an incidence of 1:500 being commonly
referenced (Cassart et al., 2006; Nehra & Goldstein, 2011; Pickhardt & Bhalla, 2002).
Gastroesophageal Reflux Disease (GERD)
GERD is a very common disorder of the GIT (Bredenoord, Pandolfino, & Smout, 2013).
It has been defined as a chronic condition developing due to significant quantities of reflux of
gastric contents into the esophagus causing symptoms with or without mucosal erosions and/or
associated complications (Chen & Hsu, 2013).
The true incidence of GERD in the general population is difficult to discern, but can be
classified in terms of its prevalence. In the adult population, GERD can be defined by at least
weekly heartburn and/or acid regurgitation, with prevalence estimates ranging from 10 to 20% in
western countries and less than 5% in Asian countries (Dent et al., 2005; El-Serag et al., 2009;
Moayyedi & Talley, 2006). The estimated prevalence of GERD in infants is considered to have a
peak incidence of approximately 50% at 4 months of age and then to decline affecting only 5%
to 10% of infants at 12 months of age (Lightdale & Gremse, 2013). Vomiting will settle in
majority of infants by 13 or 14 months of age (A. Martin et al., 2002). While this is merely an
estimate, the reported prevalence of GERD in patients of all ages worldwide is increasing
(Sherman et al., 2009). Diagnosis of GERD in infants and children can be difficult and is usually
made based upon presenting symptoms. In infants, common symptoms include regurgitation or
vomiting associated with irritability, anorexia or feeding refusal, poor weight gain, dysphagia,
presumably painful swallowing, and arching of the back during feedings. In young children, aged
1 to 5 years old, common symptoms of GERD include regurgitation, vomiting, abdominal pain,
anorexia, and feeding refusal (Gupta et al., 2006). Older children and adolescents are likely to
20
resemble a similar clinical presentation to adults with GERD including symptoms such as
heartburn, epigastric pain, chest pain, nocturnal pain, dysphagia, and unpleasant tasting burps
(Lightdale & Gremse, 2013). The two typical symptoms of GERD are recognized as pyrosis,
commonly referred to as heartburn and regurgitation, with some patients also noting extra-
oesophageal symptoms such as hoarseness, cough, and asthma (Bredenoord et al., 2013). There
is no gold standard test for objectively diagnosing GERD, and thus diagnoses have relied on a
combination of disease characteristics (Bredenoord et al., 2013).
3.3 Craniosynostosis and structural/functional anomalies of the GI system
Children with craniosynostosis syndromes may have other associated health problems
including GI malformations (Cohen & Kreiborg, 1993). Interestingly, mutations in FGFR2, the
most common gene associated with craniosynostosis syndromes have also been linked to case
reports of GI disorders. The literature on this topic is surprisingly sparse; however, there are few
studies and several of case reports on the subject.
Cohen and Kreiborg (1993) examined 135 patients with AS and concluded that only
1.5% presented with GI problems compared to 10% affected with cardiovascular anomalies,
9.6% with genitourinary anomalies 9.6%, and 1.5% with respiratory anomalies. Notably, when
autopsies were performed on 12 of these 135 patients, visceral anomalies including congenital
heart defects, anomalies of the respiratory system, GIT anomalies and genitourinary
abnormalities, were found in 9 of 12. This suggests that the percentage of anomalies from
clinical examination and history should be considered the minimum estimate because of the
possibility of clinically silent visceral anomalies, minor internal anomalies and anatomic
variations.
A recent study by Koga et al. (2012) investigated the clinical expression of PS types 2
and 3 in a Japanese population. Records of a total of 23 patients with confirmed PS diagnosis,
treated in one Japanese hospital between 1980-2011,were examined. Striking findings included
the detection of GI malformations in 22% of these patients. The detected problems included an
imperforate anus, intestinal malrotation and intestinal atresia in the affected individuals (Koga et
al., 2012).
21
Only a handful of case reports are cited in the literature ranging from 1975 to the present
documenting craniosynostosis patients who also presented with GI problems. In 1975, Eaton and
colleagues identified a patient with PS with features suggestive of type 2, who was found to have
intestinal malrotation. Barone et al, (1993) examined two patients with PS type 3, who developed
bowel obstruction and were also found to have intestinal malrotation. Park et al., (1995)
identified a mother and son both with CS and both diagnosed with epithelial- derived anal
atresia. More recently, Zarate and colleagues (2010) reported a case of a 16 month old male with
craniosynostosis who underwent cranial vault remodeling, placement of VP shunts for
hydrocephalus, gastrostomy tube for suspected GERD, tracheostomy due to bilateral choanal
stenosis, craniofacial reconstruction and posterior fossa decompression. The diagnosis of GI
malformation was very delayed resulting in significant morbidity including numerous infections
and respiratory problems. In another recent unpublished case report (2010) from the Hospital for
Sick Children (SickKids) in Toronto, an infant presented with severe bicoronal synostosis and a
diagnosis of PS, who subsequently presented with symptoms of a small bowel obstruction,
secondary to volvulus and a duodenal web.
These documented case reports have indicated the possibility that GI malformations
could be a direct effect of the FGFR gene mutation associated with craniosynostosis, a
possibility further supported by research in animal models. Specifically, all the discussed case
reports have a common finding of intestinal rotation. We therefore propose that a correlation
between FGFR-associated craniosynostosis and GIT malformations exists.
22
II. HYPOTHESIS AND OBJECTIVES
Hypothesis
We hypothesized that FGFR-related craniosynostosis is associated with GI
malformations at a greater incidence than the general population.
Objective
The aim of this study was to determine whether GI malformations occur more frequently
in the craniosynostosis population with a known FGFR mutation compared to the general
population.
23
III. MATERIALS AND METHODS
A retrospective chart review of patients diagnosed with CS, PS or AS at the Hospital for
Sick Children (SickKids) between 1990 and 2011 was performed. Approval was obtained from
the Research Ethics Board at SickKids (Appendix A & B),
Inclusion criteria of charts to be included for review included the following:
a) Record of genetic counseling, testing or discussion.
b) Diagnosis of a craniosynostosis syndrome (CS, PS or AS)
c) Identification of a mutation in FGFR1, 2 or 3 genes
d) Documentation of a GI malformation according to the EUROCAT classification system
and common congenital GI malformations seen at SickKids
Exclusion criteria included:
a) Incomplete medical records
b) Lack of documented evidence of mutations in FGFR1, 2 or 3.
Three databases were searched for patients meeting the study inclusion criterion:
i) Division of Clinical and Metabolic Genetics clinical database (SHIRE systems)
ii) Department of Paediatric Laboratory Medicine molecular genetics database (SHIRE
systems), and
iii) Division of Plastic Surgery craniofacial database.
Medical records of the selected patients treated at SickKids included review of molecular
genetic test reports, general clinic letters, consultations, diagnostic imaging reports, clinic notes
for plastic surgery, genetics and GI visits and emergency records. These charts were reviewed
using a systematic approach that included a step-by-step analysis of all the records contained in
each patient folder to assess for a definitive diagnosis of craniosynostosis, the presence of
mutations in FGFR1, 2 or 3 genes, and any record of gastrointestinal abnormalities. If GIT
abnormalities were noted, they were classified using the EUROCAT classification system
(http://www.eurocat-network.eu/) for the following GIT anomalies:
i) oeshophageal atresia with or without tracheo-oesophageal fistula
ii) intestinal malrotation, stenosis or atresia,
24
iii) GERD
iv) ano-rectal atresia or stenosis
v) Hirschsprung's disease,
vi) atresia of the bile ducts
vii) annular pancreas,
viii) diaphragmatic hernia,
ix) gastroschisis,
x) omphalocele
In addition, the investigation was further expanded to include findings of clefts of the
palate and/or lip. Findings were documented in a coded spreadsheet to preserve patient
anonymity.
Statistical analysis:
Statistical analysis was carried out by an independent statistician. A power calculation
and a binomial test was conducted to establish the statistical significance of the deviation in the
proportion of patients with GIT malformations in this sample compared to that of the general
population, at the 0.05 significance level.
25
IV. RESULTS
1. Patient sample:
A total of 32 patient charts were identified that met all the inclusion criteria of the study.
An initial review of the three databases of patients treated at SickKids between 1990 and 2011
identified a total of 50 charts of patients with clinical diagnoses of CS, PS and AS. As SickKids
is a hospital for children, all patients were 18 years of age or younger. Out of the 50 charts
identified initially, 18 patients were excluded from the study: 5 were due to inadequate health
records, 8 to a lack of documentation of genetic testing for FGFR1, 2 or 3, and 5 due to the
documented absence of a detectable FGFR mutation.
The 32 patient charts were reviewed for the congenital GIT malformations as described
in the EUROCAT classification system and/or frequently encountered at SickKids.
2. Craniosynostosis syndromes and mutations:
Of the 32 patients that met the inclusion criteria, 10 were diagnosed with CS, 7 with PS
and 15 with AS (Tables 3 and 4). All 32 patients were found to have documented FGFR2
mutations. Information on the specific mutations was only available for 25 patients. In total, 16
different mutations were identified in the 25 patients (Table 4 and Figure 3).
Of the 10 patients diagnosed with CS, all mutations were missense mutations in the IgIII
domain of FGFR2. Three out of the 10 mutations were in codon 342, with the change of the
cysteine (Cys) residue to tyrosine (Tyr), phenylalanine (Phe) and serine (Ser). The other
mutations included changes in codons 290, 328, and 344.
PS patients in the sample contained missense mutations in the IgIII domain, and in the
linker region between IgII and IgIII (S252) of FGFR2. In two of these patients, there was a
change in codon 342 from Cys to arginine (Arg). A splice-site mutation was identified in the
IgIII domain of FGFR2.
26
Of the 15 patients diagnosed with AS, 4 lacked documentation regarding the specific
FGFR2 mutation. One patient was found to have a large intronic deletion of 1372 base pairs (bp)
between FGFR2 exons IIIb and IIIc. The remaining 10 patients had missense mutations in the
linker region between IgII and IgIII in either Ser252 or proline (Pro)253. Seven of these 10
patients presented with a mutation at codon 252 from Ser to tryptophan (Trp), while three
patients presented with a mutation at codon 253 from Pro to Arg.
Table 3: Number and type of mutations identified in a sample of 32 FGFR-associated
craniosynostosis syndromic patients at the Hospital for Sick Children (Toronto, Ontario) between
the years of 1990-2011.
Crouzon Syndrome (CS)
Pfeiffer Syndrome (PS)
Apert Syndrome (AS)
No. of patients 10 7 15 Summary of type and Location of Mutations
-‐ Missense mutations in IgIII domain of FGFR2
-‐ Missense mutations in IgIII domain of FGFR2
-‐ Missense mutations in Ser252 of FGFR2
-‐ Missense mutations in Ser252 and Ppo253 of FGFR2
-‐ Deletion mutation in FGFR2
27
Table 4: Observed Fibroblast Growth Factor Receptor mutations and associated findings. IM -
intestinal (bowel) malrotation; GERD - gastroesophageal reflux disease; CP- cleft palate; CL -
cleft lip; * likely reporting error in mutation nomenclature.
28
Figure 3: Distribution and types of mutations observed in the sample population of CS, PS and
AS patients (pictured above FGFR2 protein).
3. GIT anomalies
The review of the charts for GIT abnormalities according to the EUROCAT classification
system revealed a relative absence of documentation of most GI problems. The most common
abnormalities observed were intestinal/bowel malrotation (IM) and GERD.
Three out of 32 patients were found to have IM, and also exhibited GERD (Table 4). Of
the three patients with IM, two of them were diagnosed with PS, with the mutation cysteine to
arginine in codon 342. The third patient was diagnosed with AS with a mutation in codon 252
with a change from serine to tryptophan.
29
Table 5: Frequency of Intestinal/Bowel Malrotation and GERD in the sample population of CS,
PS and AS patients.
GERD Malrotation
Sample Size Frequency (% of total) Frequency (% of total)
Apert 15 3 9.375 1 3.13 Pfeiffer 7 2 6.25 2 6.25 Crouzon 10 2 6.25 0 0 Total 32 7 21.875 3 9.38
The incidence in the general population of IM is 1 in 500 (pgenral=0.002) (Cassart et al.,
2006; Nehra & Goldstein, 2011; Pickhardt & Bhalla, 2002). Statistical analysis comparing the
incidence of IM in this sample population revealed a significantly higher incidence of this GI
abnormality compared to the general population (p < 0.05), thus we conclude that the proportion
with intestinal malrotation in our sample is greater than that of the general population.
Seven out of 32 patients were found to have GERD (Table 5). Three were AS patients,
two were PS and one was a CS patient. No apparent pattern of genetic mutations is evident. The
true incidence of GERD in the general population is very difficult to discern and estimated at 10-
20% in western countries (Dent et al., 2005; El-Serag et al., 2009; Moayyedi & Talley, 2006).
The incidence of 21.75% (7/32) in the sample population appeared to be similar to the incidence
found in the general population in western countries.
Cleft palate (CP) was identified in a total of 12 cases. Nine cases were found in patients
with AS, 1 in a patient with PS and two in patients with CS. A total of seven cases with CP
displayed a mutation in codon 252 with a change from serine to tryptophan, while one case of CP
was found in a patient with a mutational change from cysteine to arginine in codon 342. The
remaining four cases identified with CP did not have documentation available of specific
mutation involved.
30
4. Summary
In summary, the major findings of our study are:
1. The sample of 32 patient charts reveals 16 different genetic mutations in the FGFR2 gene.
2. Mutations in CS patients were found in the IgIII domains, mutations in PS patients occurred in
both the IgIII domain, and in the linker region between IgII and IgIII (Ser252) of FGFR2, and
mutations in AS patients were found in the linker region between IgII and IgIII in either Ser252
or Pro253.
3. The incidence of IM was significantly higher in the sample population compared to the
incidence reported in the general population.
4. The incidence of CP was found almost exclusively in AS involving the p.Ser252Trp mutation.
31
V. DISCUSSION
This study showed a statistically significant association between FGFR-associated
craniosynostosis and specific GI defects. To our knowledge, no studies to date have examined
this population to look for this specific morbidity involving the GIT. Our study addresses this by
reviewing the hospital records of a group of FGFR-associated craniosynostosis syndromic
patients for the occurrence of GIT malformations.
1. Genetic findings in sample population
The current study found a total of 16 different genetic mutations in the 32 patient charts
reviewed. Generally, the mutations observed in our cohort are similar to those previously
documented in the literature. There has been quite extensive documentation of mutations in
FGFR2 at codon 342, as well as 290 and 278 in both CS and PS patients and are regarded as
mutational hotspots (Schaefer et al., 1998; Kress et al., 2001) The literature shows that
mutations at codon 342, such as p.Cys342Arg and p.Cys342Trp tend to occur most frequently on
the FGFR2 gene (Kress et al., 2001). Other commonly found mutations in individuals with CS
and PS include p.Trp290Gly, p.Trp290Arg, p.Tyr340His and p.Cys278Phe mutation (Lajeunie et
al, 2006; Kress et al, 2001, Park et al , 1995). Indeed, this was also the observation made in our
study. Codon 342 appeared to be the most common codon affected in the sample population.
Mutational changes of the cysteine residue to either Tyr, Phe or Ser were found in three CS
patients and to Cys or Arg in two PS patients. Further, a mutation at codon 290 from Trp to Gly
was observed in a CS patient. In addition to the missense mutations noted, one PS patient in our
cohort sample exhibited a splice site mutation at 952-1G>A. The mutation of this patient has
been previously described by Teebi and colleagues (2002).
In our study, two patients exhibiting intestinal malrotation were found to have the
p.Cys342Arg mutation in the FGFR2 gene. This particular mutation, along with p.Ser351Cys,
p.Trp290Cys has been detected in the more severe phenotypic displays of PS (Johnson & Wilkie,
2011).
32
Previous studies have reported that 98% of AS cases can be accounted for by two
mutations 1) p.Ser252Trp and 2) p.Pro253Arg (Ferreira et al., 1999; Johnson & Wilkie, 2011).
Literature suggests that the p.Ser252Trp mutation accounts for approximately two-thirds of the
AS cases and the p.Pro253Arg mutation for the other third (Ferreira et al., 1999; Johnson &
Wilkie, 2011). Similar proportions were observed in our study, with the p.Ser252Trp mutation
occurring more often than the p.Pro253Arg mutation. Phenotype-genotype correlations for these
specific mutations have been previously documented. Individuals with an FGFR2 mutation of
p.Ser252Trp tend to present more often with cleft palates, severe ocular problems and
nasolacrimal stenosis (Akai et al., 2006). Patients with p.Pro253Arg in the FGFR2 gene often
display more intellectual disability and greater degrees of syndactyly (Akai et al., 2006; Jadico et
al., 2006; Johnson & Wilkie, 2011; Slaney et al., 1996). The sample population in our study also
supports these previously documented findings with six out of seven individuals with
p.Ser252Trp mutation displaying cleft palates. The AS patient exhibiting a large intronic deletion
was found to harbour a heterozygous 1372 bp deletion between FGFR2 exons IIIb and IIIc, This
apparently originated from recombination between 13 bp of identical DNA sequence present in
both exons and was not found in the unaffected parents (Fenwick et al., 2011).
2. Intestinal malrotation in sample population
Our findings suggest an association between FGFR-related craniosynostosis and GI
malformations, in particular bowel malrotation. The results show a statistically significant
difference in the number of FGFR-associated craniosynostosis patients that present with an
intestinal (bowel) malrotation when compared to the normal population. Patients in our cohort
are approximately 47 times more likely to have bowel malrotation. These results support our
hypothesis that FGFR-related craniosynostosis is associated with GI malformations. These
findings are not surprising given what is already known about FGFR involvement in normal
growth and development. They are further supported by multiple mouse model experiments, case
reports and clinical studies, revealing GIT anomalies in the syndromic craniosynostosis
populations (Barone et al., 1993; Cohen & Kreiborg, 1993; Eaton et al., 1975; Fairbanks et al.,
2004; Gong, 2012; Johnson & Wilkie, 2011; Lajeunie et al., 1999; Mai et al., 2010; Oldridge et
33
al., 1997; Park et al., 1995; Passos-Bueno et al., 1999; Wilkie, 2001; Wilkie et al., 1995; Zarate
et al., 2010).
Several studies examining phenotypic expression in the human FGFR-associated
craniosynostosis populations similarly point towards such correlations. A retrospective study by
Koga and colleagues (2012), carried out in Japan, has cited repeated malformations in the GIT as
part of their findings. In their sample population, 22% of the PS patients exhibited GIT
malformations including an imperforate anus, and intestinal malrotation (Koga et al., 2012). Our
study showed similar results with 25% of PS patients presenting with some type of GIT
malformation. Cohen and Kreiborg's, (1993) study thoroughly examined 136 AS cases and
concluded that 1.5% of living patients presented with clinically identifiable GIT problems.
Furthermore, a large majority of deceased patients (9 out of 12) possessed visceral anomalies.
This suggests that the percentage of anomalies identified during clinical examination and history
taking should be considered the minimum estimate. They suggest that clinically silent visceral
anomalies, minor internal anomalies and other anatomic variations in syndromic
craniosynostosis cases may be more prevalent than initial presentation suggests.
Our study also proposes that GI anomalies in the FGFR-associated craniosynostosis
population may not be an infrequent finding. Over the past three and a half decades, six case
reports have documented the finding of a GIT anomaly in FGFR-associated craniosynostosis
patients. Some of these case reports illustrate the importance of early recognition of GIT
malrotation as a possible comorbidity associated with FGFR-related craniosynostosis syndromes.
Our study identified two PS patients and an AS patient with intestinal malrotation. One of the
PS patients exhibited findings consistent with intestinal malrotation that was diagnosed during
her second year of life. This patient had a jejunum that lay to the right of the midline, her cecum
was abnormally located superomedially and the ascending colon was on a horizontal plane with
the cecum directed medially. Another one of our identified PS was an infant who presented with
PS and subsequently presented with a small bowel obstruction secondary to volvulus and a
duodenal web. Fortunately, prompt diagnosis was able to avoid further morbidity in this case.
Lastly, the AS patient with intestinal malrotation identified in this study was discovered later in
life as a result of a history of recurrent vomiting and abdominal pain. These previous case
reports and the three cases identified in this study highlight the importance of recognizing GIT
malformation as a possible comorbidity to FGFR-related craniosynostosis syndromes.
34
3. Proposed mechanism
The anatomical development of the GIT is a complex process occurring in three distinct
phases: i) an early phase of umbilical cord herniation, lasting from weeks 5-10 weeks of
embryogenesis followed by ii) a stage of reduction of the midgut loop back into the abdomen
occurring at weeks 10-11 and finally iii) a period of fixation from the 12th week of development
lasting until after birth (Frazer & Robbins, 1915; Mall, 1898; Strouse, 2004). In the early
embryo, the GIT is a straight tube supplied by the superior mesenteric artery (SMA). The midgut
lengthens disproportionally to the embryo, forming a U-shaped loop that herniates into the base
of the umbilical cord at approximately 6 weeks of gestation. Coincident with this growth, the
small intestine rotates a total of 270 degrees in an anti-clockwise direction being completed by
the 10th week when the intestine transitions back to the abdomen (Martin & Shaw-Smith, 2010).
Malrotation of the intestine is a broad term used to collectively describe any failure of rotation
that alters the normal developmental process of any part of the intestinal tract. It is not a single
distinct entity, but rather a continuum of abnormalities occurring during development of the
midgut. Martin and Shaw-Smith (2010) suggest that four etiologies may be attributed for
intestinal malrotations. These include: i) abnormalities of left and right patterning, ii)
abnormalities of the dorsal mesentery, iii) abnormalities of the bowel and iv) incorrect placement
of the intestine or abdominal organs.
For our purposes, we can consider the proposed roles of FGF signaling during
embryogenesis to suggest a link between FGFR-associated craniosynostosis and GIT
malrotation. It has been shown that FGF signaling is crucial in many aspects of early
embryogenesis, including the coordination of morphogenetic movements including dorsoventral,
anterioposterior and left-right (L/R) axis determination (Dorey & Amaya, 2010). In the sea
urchin both the fgfA ligand, and the fgfr2 receptor are necessary for the migration of the primary
mesenchyme cells (Röttinger et al., 2008). Similarly in Drosophila, a mutation in the fgfr2 gene
results in the failure of mesodermal cells to migrate away from the midline during gastrulation
(Beiman et al., 1996; Gisselbrecht, et al., 1996). The L/R axis is the third axis to be established in
the embryo and is responsible for the asymmetric placement of the thoracic and abdominal
organs, including what is considered the normal positioning of the bowel (Dorey & Amaya,
2010).
35
Studies in mouse, chick, rabbit and zebrafish have demonstrated a direct role in FGF
signaling in L/R axis determination (Albertson & Yelick, 2005; Boettger et al., 1999; Fischer et
al., 2002; Meyers & Martin, 1999). In all vertebrates, the L/R axis appears to originate from a
fluid flow in the node, a closed depression on the ventral surface of the embryo (Essner et al.,
2002; Nonaka et al., 1998). This extraembryonic fluid undergoes a leftward flow that is set into
motion by polarized monocilia and is thought to be responsible for normal situs (Tanaka et al.,
2005). FGF signaling seems to play several important roles during this early step of L/R axis
determination and may be responsible for the formation of cilia, cilia length (Neugebauer et al.,
2009), and for the release of vesicular nodal parcels (VNPs) containing morphogens–Sonic
hedgehog (SHH) and retinoic acid (RA)–into the node of the mouse (Tanaka et al., 2005). Any
genetic mutation that could interfere with nodal fluid flow altering L/R patterning of the dorsal
mesentery, the intestine and other abdominal contents may lead to intestinal malrotation.
Further support for this plausible proposed mechanism can be extrapolated from the
Cohen and Kreiborg (1993) study of AS patients. These authors report many different visceral
anomalies afflicting these patients including examples of L/R patterning problems such as
pulmonary stenosis, dextocardia, mesocardia and dextrorotation in the cardiovascular system and
partial biliary atresia with agenesis of the gallbladder in the GI system (Cohen & Kreiborg, 1993;
Lindsay, Black, & Jr., 1975; Ofodile & Adeloye, 1982).
4. Study limitations
This study was retrospective in nature. Inherent limitations of retrospective study designs
include the reliance on the accuracy of written record, which at times may be sparse or
inaccessible. Although SickKids maintains a thorough record of all patients treated, while
reviewing hospital records, inconsistencies in nomenclature and reporting errors were identified.
We observed a probable documentation error in the charts of three CS patients who likely had a
mutation recorded incorrectly. In these cases, the documented amino acid change did not match
the genomic sequence; thus, we conclude that a typographical error must have occurred.
Furthermore, potential biases could exist in our sample population. It is possible that
since SickKids is a leading paediatric hospital in North America, with a craniofacial program,
36
parents of children with craniosynostosis may tend to seek out a multidisciplinary center such as
SickKids for all of their care. This could potentially increase the number of patients with
intestinal malrotation seen at SickKids. Alternatively, and more likely, many patients travel great
distances to seek care in the craniofacial program at SickKids, but when a GIT issue arises, these
individuals may be more likely to see their local physician or hospital for relatively mild
symptoms or because they may not associated the two problems of craniofacial and GIT
anomalies together. Thus, it is quite possible that our sample may represent an
underascertainment of the true incidence of rotation in this craniosynostosis population.
37
VI. FUTURE DIRECTIONS
The findings of this study suggest a correlation between FGFR-related craniosynostosis
syndromes and GIT malformations. However, a direct cause and effect relationship cannot be
ascertained. Further research will need to be conducted to confirm this relationship. While the
findings of retrospective studies can be very useful in generating thought provoking data, they
are only hypothesis generating, and thus are most useful to suggest future directions for research.
We proposed that an FGFR gene mutation is involved in the malformation of the gut
solely based upon the evidence presented in current literature. Future directions for research
could involve using a multi-center approach to look at a greater quantity of these FGFR-
associated syndromic cases. Conducting a study to examine patients with craniosynostosis and a
known FGFR mutation compared to patients with craniosynostosis but no FGFR mutation to
discern any differences that are noted in the GIT may shed further light on the potential
widespread impact an FGFR mutation can exert.
38
VII. CONCLUSION
Our study supports the theory that intestinal/bowel malrotations in an FGFR-associated
craniosynostoses population are more likely to occur compared to the general population.
According to the current management protocol, screening of GIT disorders is not a part of the
investigative procedures in the care of CS patients. This study provides a sound scientific
rationale for the possible implementation of changes, e.g., additional testing and screening
procedures for GIT problems, in the clinical management of patients with FGFR-associated
craniosynostosis.
The findings of our study support a plausible explanation for the discovery of GIT
anomalies, specifically intestinal malrotation in craniosynostosis syndromes. The involvement of
FGFR in the normal growth and development of the GIT provides a sound scientific rationale for
the anomalies occurring in cases where mutations involving this gene occur. In addition,
research in animal models, the few studies and case reports demonstrating GIT further supports
the plausible correlation between FGFR-associated craniosynostosis and GIT malformations.
This, we speculate that GIT anomalies are a direct result of mutations occurring in the FGFR
altering the normal pathway of development and growth yielding malformations.
39
VIII. REFERENCES
Aisenson, M.R. (1950). Closing of the anterior fontanelle. Pediatrics, 6(2), 223–6.
Akai, T., Yamamoto, K., Iizuka, H., Kawakami, S., Yoshida, J., Kakinuma, H., Yaguchi, Y.,
Ozawa, T. (2006). Syndromic craniosynostosis with elbow joint contracture. Pediatric
neurosurgery, 42(2), 108–12. doi:10.1159/000090465
Albertson, R.C., & Yelick, P.C. (2005). Roles for fgf8 signaling in left-right patterning of the
visceral organs and craniofacial skeleton. Developmental biology, 283(2), 310–21.
doi:10.1016/j.ydbio.2005.04.025
Anderson, J., Burns, H.D., Enriquez-Harris, P., Wilkie, a O., & Heath, J.K. (1998). Apert
syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF
ligand. Human molecular genetics, 7(9), 1475–83.
Barone, C.M., Marion, R., Shanske, a, Argamaso, R.V, & Shprintzen, R.J. (1993). Craniofacial,
limb, and abdominal anomalies in a distinct syndrome: relation to the spectrum of Pfeiffer
syndrome type 3. American journal of medical genetics, 45(6), 745–50.
doi:10.1002/ajmg.1320450616
Beiman, M., Shilo, B.Z., & Volk, T. (1996). Heartless, a Drosophila FGF receptor homolog, is
essential for cell migration and establishment of several mesodermal lineages. Genes &
development, 10(23), 2993–3002.
Boettger, T., Wittler, L., & Kessel, M. (1999). FGF8 functions in the specification of the right
body side of the chick. Current biology : CB, 9(5), 277–80.
Bredenoord, A.J., Pandolfino, J.E., & Smout, A.J.P.M. (2013). Gastro-oesophageal reflux
disease. The Lancet, 381(9881), 1933–42. doi:10.1016/S0140-6736(12)62171-0
Burke, D., Wilkes, D., Blundetl, T.L., & Malcolm, S. (1998). Fibroblast growth factor receptors :
lessons from the genes, (February), 59–62.
40
Cassart, M., Massez, A., Lingier, P., Absil, A.-S., Donner, C., & Avni, F. (2006). Sonographic
prenatal diagnosis of malpositioned stomach as a feature of uncomplicated intestinal
malrotation. Pediatric radiology, 36(4), 358–60. doi:10.1007/s00247-005-0074-1
Chen, C.-L., & Hsu, P.-I. (2013). Current Advances in the Diagnosis and Treatment of
Nonerosive Reflux Disease. Gastroenterology Research and Practice, 2013, 1–8.
doi:10.1155/2013/653989
Chen, C.-P., Lin, S.-P., Su, Y.-N., Chien, S.-C., Tsai, F.-J., & Wang, W. (2008).
Craniosynostosis and congenital tracheal anomalies in an infant with Pfeiffer syndrome
carrying the W290C FGFR2 mutation. Genetic counseling (Geneva, Switzerland), 19(2), 165–
72.
Chumas, P.D., Cinalli, G., Arnaud, E., Marchac, D., & Renier, D. (1997). Classification of
previously unclassified cases of craniosynostosis. Journal of neurosurgery, 86(2), 177–81.
doi:10.3171/jns.1997.86.2.0177
Cohen, M.M. (1988). Craniosynostosis update 1987. American journal of medical genetics.
Supplement, 4, 99–148.
Cohen, M.M. (2002). Malformations of the craniofacial region: evolutionary, embryonic,
genetic, and clinical perspectives. American journal of medical genetics, 115(4), 245–68.
doi:10.1002/ajmg.10982
Cohen, M.M., & Kreiborg, S. (1993). Visceral anomalies in the Apert syndrome. American
journal of medical genetics, 45(6), 758–60. doi:10.1002/ajmg.1320450618
Cohen, M.M., & MacLean, R.E. (2000). Craniosynostosis: diagnosis, evaluation and
management (2nd editio.). Oxford University Press.
Cornejo-Roldan, L.R., Roessler, E., & Muenke, M. (1999). Analysis of the mutational spectrum
of the FGFR2 gene in Pfeiffer syndrome. Human genetics, 104(5), 425–31.
Coussens, A.K., Wilkinson, C.R., Hughes, I.P., Morris, C.P., van Daal, A., Anderson, P.J., &
Powell, B. C. (2007). Unravelling the molecular control of calvarial suture fusion in children
with craniosynostosis. BMC genomics, 8, 458. doi:10.1186/1471-2164-8-458
41
Cunningham, M., Seto, M., Ratisoontorn, C., Heike, C., & Hing, A. (2007). Syndromic
craniosynostosis : from history to hydrogen bonds. Orthodontics & Craniofacial Research,
10, 67–81.
Dab, S., Sokhi, R., Lee, J.-C., Sessle, B.J., Aubin, J.E., & Gong, S.-G. (2013). Characterization
of esophageal defects in the Crouzon mouse model. Birth defects research. Part A, Clinical
and molecular teratology, 97(9), 578–86. doi:10.1002/bdra.23172
Decker, J.D., & Hall, S.H. (1985). Light and electron microscopy of the new born sagittal suture.
The Anatomical record, 212(1), 81–9. doi:10.1002/ar.1092120112
Dent, J., El-Serag, H.B., Wallander, M., & Johansson, S. (2005). Epidemiology of gastro-
oesophageal reflux disease: a systematic review. Gut, 54(5), 710–7.
doi:10.1136/gut.2004.051821
Derderian, C., & Seaward, J. (2012). Syndromic craniosynostosis. Seminars in plastic surgery,
26(2), 64–75. doi:10.1055/s-0032-1320064
Dorey, K., & Amaya, E. (2010). FGF signalling: diverse roles during early vertebrate
embryogenesis. Development (Cambridge, England), 137(22), 3731–42.
doi:10.1242/dev.037689
Du, X., Xie, Y., Xian, C.J., & Chen, L. (2012). Role of FGFs/FGFRs in skeletal development
and bone regeneration. Journal of cellular physiology, 227(12), 3731–43.
doi:10.1002/jcp.24083
Eaton, A.P., Sommer, A., & Sayers, M.P. (1975). The Kleeblattschädel anomaly. Birth defects
original article series, 11(2), 238–46.
El-Serag, H., Hill, C., & Jones, R. (2009). Systematic review: the epidemiology of gastro-
oesophageal reflux disease in primary care, using the UK General Practice Research Database.
Alimentary pharmacology & therapeutics, 29(5), 470–80. doi:10.1111/j.1365-
2036.2008.03901.x
Essner, J.J., Vogan, K.J., Wagner, M.K., Tabin, C.J., Yost, H.J., & Brueckner, M. (2002).
Conserved function for embryonic nodal cilia. Nature, 418(6893), 37–8. doi:10.1038/418037a
42
Eswarakumar, V.P., Lax, I., & Schlessinger, J. (2005). Cellular signaling by fibroblast growth
factor receptors. Cytokine & growth factor reviews, 16(2), 139–49.
doi:10.1016/j.cytogfr.2005.01.001
European Surveillance of Congenital Anomalies. Cited at http://www.eurocat-network.eu
Fairbanks, T.J., Kanard, R., Del Moral, P.M., Sala, F.G., De Langhe, S., Warburton, D.,
Anderson, K.D., Bellusci, S., & Burns, R.C. (2004). Fibroblast growth factor receptor 2 IIIb
invalidation—a potential cause of familial duodenal atresia. Journal of Pediatric Surgery,
39(6), 872–874. doi:10.1016/j.jpedsurg.2004.02.026
Fenwick, A.L., Bowdin, S.C., Klatt, R.E.M., & Wilkie, A.O.M. (2011). A deletion of FGFR2
creating a chimeric IIIb/IIIc exon in a child with Apert syndrome. BMC medical genetics,
12(1), 122. doi:10.1186/1471-2350-12-122
Ferreira, J.C., Carter, S.M., Bernstein, P.S., Jabs, E.W., Glickstein, J.S., Marion, R.W., Baergen,
R.N., & Gross, S.J. (1999). Second-trimester molecular prenatal diagnosis of sporadic Apert
syndrome following suspicious ultrasound findings. Ultrasound in obstetrics & gynecology :
the official journal of the International Society of Ultrasound in Obstetrics and Gynecology,
14(6), 426–30. doi:10.1046/j.1469-0705.1999.14060426.x
Fischer, A., Viebahn, C., & Blum, M. (2002). FGF8 acts as a right determinant during
establishment of the left-right axis in the rabbit. Current biology : CB, 12(21), 1807–16.
Florisson, J.M.G., Verkerk, A.J.M.H., Huigh, D., Hoogeboom, a J.M., Swagemakers, S.,
Kremer, A., Heijsman, D., Lequin, M.H., Mathijssen, I.M.J., & van der Spek, P. J. (2013).
Boston type craniosynostosis: report of a second mutation in MSX2. American journal of
medical genetics. Part A, 161(10), 2626–33. doi:10.1002/ajmg.a.36126
Forrest, C.R., & Hopper, R.A. (2013). Craniofacial syndromes and surgery. Plastic and
reconstructive surgery, 131(1), 86e–109e. doi:10.1097/PRS.0b013e318272c12b
Frazer, J.E., & Robbins, R.H. (1915). On the Factors concerned in causing Rotation of the
Intestine in Man. Journal of anatomy and physiology, 50(Pt 1), 75–110.
43
Gisselbrecht, S., Skeath, J.B., Doe, C.Q., & Michelson, A.M. (1996). Heartless encodes a
fibroblast growth factor receptor (DFR1/DFGF-R2) involved in the directional migration of
early mesodermal cells in the Drosophila embryo. Genes & development, 10(23), 3003–17.
Gong, S.-G. (2012). The Fgfr2 W290R mouse model of Crouzon syndrome. Child’s nervous
system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 28(9),
1495–503. doi:10.1007/s00381-012-1792-y
Gonzales, M., Heuertz, S., Martinovic, J., Delahaye, S., Bazin, A, Loget, P., Pasquier, L.,
LeMerrer, M., & Bonaventure, J. (2005). Vertebral anomalies and cartilaginous tracheal
sleeve in three patients with Pfeiffer syndrome carrying the S351C FGFR2 mutation. Clinical
genetics, 68(2), 179–81. doi:10.1111/j.1399-0004.2005.00477.x
Gupta, S.K., Hassall, E., Chiu, Y.-L., Amer, F., & Heyman, M.B. (2006). Presenting symptoms
of nonerosive and erosive esophagitis in pediatric patients. Digestive diseases and sciences,
51(5), 858–63. doi:10.1007/s10620-006-9095-3
Hockstein, N.G., McDonald-McGinn, D., Zackai, E., Bartlett, S., Huff, D.S., & Jacobs, I.N.
(2004). Tracheal anomalies in Pfeiffer syndrome. Archives of otolaryngology--head & neck
surgery, 130(11), 1298–302. doi:10.1001/archotol.130.11.1298
Hughes, S. E. (1997). Differential Expression of the Fibroblast Growth Factor Receptor (FGFR)
Multigene Family in Normal Human Adult Tissues. Journal of Histochemistry &
Cytochemistry, 45(7), 1005–1019. doi:10.1177/002215549704500710
Ibrahimi, O.A., Eliseenkova, A.V, Plotnikov, A.N., Yu, K., Ornitz, D.M., & Mohammadi, M.
(2001). Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
Itoh, N., & Ornitz, D.M. (2004). Evolution of the Fgf and Fgfr gene families. Trends in genetics :
TIG, 20(11), 563–9. doi:10.1016/j.tig.2004.08.007
Jabs, E.W., Müller, U., Li, X., Ma, L., Luo, W., Haworth, I.S., Klisak, I., Sparkes, R., Warman,
M.L., & Mulliken, J. B. (1993). A mutation in the homeodomain of the human MSX2 gene in
a family affected with autosomal dominant craniosynostosis. Cell, 75(3), 443–50.
44
Jadico, S.K., Young, D.A., Huebner, A., Edmond, J.C., Pollock, A.N., McDonald-McGinn, D.
M., Li, Y.-J., Zackai, E.H., & Young, T. L. (2006). Ocular abnormalities in Apert syndrome:
genotype/phenotype correlations with fibroblast growth factor receptor type 2 mutations.
Journal of AAPOS : the official publication of the American Association for Pediatric
Ophthalmology and Strabismus / American Association for Pediatric Ophthalmology and
Strabismus, 10(6), 521–7. doi:10.1016/j.jaapos.2006.07.012
Jaye, M., Schlessinger, J., & Dionne, C.A. (1992). Fibroblast growth factor receptor tyrosine
kinases: molecular analysis and signal transduction. Biochimica et biophysica acta, 1135(2),
185–99.
Johansen, V.A., & Hall, S.H. (1982). Morphogenesis of the Mouse Coronal Suture. Cells Tissues
Organs, 114, 58–67.
Johnson, D., & Wilkie, A.O.M. (2011). Craniosynostosis. European journal of human genetics :
EJHG, 19(4), 369–76. doi:10.1038/ejhg.2010.235
Kabbani, H., & Raghuveer, T.S. (2004). Craniosynostosis. American family physician, 69(12),
2863–70.
Kaplan, L.C. (1991). Clinical assessment and multispecialty management of Apert syndrome.
Clinics in plastic surgery, 18(2), 217–25.
Kimonis, V., Gold, J.-A., Hoffman, T.L., Panchal, J., & Boyadjiev, S.A. (2007). Genetics of
craniosynostosis. Seminars in pediatric neurology, 14(3), 150–61.
doi:10.1016/j.spen.2007.08.008
Koga, H., Suga, N., Nakamoto, T., Tanaka, K., & Takahashi, N. (2012). Clinical expression in
Pfeiffer syndrome type 2 and 3: surveillance in Japan. American journal of medical genetics.
Part A, 158A(10), 2506–10. doi:10.1002/ajmg.a.35590
Kokich, V. G. (1976). Age changes in the human frontozygomatic suture from 20 to 95 years.
American journal of orthodontics, 69(4), 411–30.
45
Kress, W., Collmann, H., Büsse, M., Halliger-keller, B., & Mueller, C.R. (2000). Clustering of
FGFR2 gene mutations in patients with Pfeiffer and Crouzon syndromes ( FGFR2-associated
craniosynostoses ). Cytogenetics and Cell Genetics, 91, 134–137.
Kumar, S.B.V.S., Narasu, L., Gundla, R., Dayam, R., & J A R P, S. (2013). Fibroblast growth
factor receptor inhibitors. Current pharmaceutical design, 19(4), 687–701.
Lajeunie, E., Cameron, R., El Ghouzzi, V., De Parseval, N., Journeau, P., Gonzales, M.,
Delezoide, A.-L., Bonaventure, J., Le Merrer, M., & Renier, D. (1999). Clinical variability in
patients with Apert’s syndrome. Journal of Neurosurgery, 90, 443–447.
Lajeunie, E., Heuertz, S., El Ghouzzi, V., Martinovic, J., Renier, D., Le Merrer, M., &
Bonaventure, J. (2006). Mutation screening in patients with syndromic craniosynostoses
indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of
Pfeiffer syndrome. European journal of human genetics : EJHG, 14(3), 289–98.
doi:10.1038/sj.ejhg.5201558
Lajeunie, E., Le Merrer, M., Bonaïti-Pellie, C., Marchac, D., & Renier, D. (1995). Genetic study
of nonsyndromic coronal craniosynostosis. American journal of medical genetics, 55(4), 500–
4. doi:10.1002/ajmg.1320550422
Levi, B., Wan, D.C., Wong, V.W., Nelson, E., Hyun, J., & Longaker, M.T. (2012). Cranial
suture biology: from pathways to patient care. The Journal of craniofacial surgery, 23(1), 13–
9. doi:10.1097/SCS.0b013e318240c6c0
Lightdale, J.R., & Gremse, D.A. (2013). Gastroesophageal reflux: management guidance for the
pediatrician. Pediatrics, 131(5), e1684–95. doi:10.1542/peds.2013-0421
Lindsay, J., Black, F., & Jr., D.W. (1975). Acrocephalosyndactly (Apert’s syndrome): Temporal
bone findings. The Annals of Otology, Rhinology & Laryngology, 84, 174–8.
Mai, S., Wei, K., Flenniken, A., Adamson, S. L., Rossant, J., Aubin, J. E., & Gong, S.-G. (2010).
The missense mutation W290R in Fgfr2 causes developmental defects from aberrant IIIb and
IIIc signaling. Developmental dynamics : an official publication of the American Association
of Anatomists, 239(6), 1888–900. doi:10.1002/dvdy.22314
46
Mall, F. (1898). Development of the human intestine and its position in the adult. Bull Johns
Hopkins Hosp, 9, 197–208.
Mangasarian, K., Li, Y.A.N., Mansukhani, A., & Basilico, C. (1997). Mutation Associated With
Crouzon Syndrome Causes Ligand-Independent Dimerization and Activation of FGF,
125(February), 117–125.
Mansukhani, A., Bellosta, P., Sahni, M., & Basilico, C. (2000). Signaling by Fibroblast Growth
Factors ( FGF ) and Fibroblast Growth Factor Receptor 2 ( FGFR2 )– activating Mutations
Blocks Mineralization and Induces Apoptosis in Osteoblasts, 149(6), 1297–1308.
Marie, P.J. (2003). Fibroblast growth factor signaling controlling osteoblast differentiation.
Gene, 316, 23–32. doi:10.1016/S0378-1119(03)00748-0
Marie, P.J., Miraoui, H., & Sévère, N. (2012). FGF/FGFR signaling in bone formation: progress
and perspectives. Growth factors (Chur, Switzerland), 30(2), 117–23.
doi:10.3109/08977194.2012.656761
Martin, A., Pratt, N., Kennedy, J., Ryan, P., Ruffin, R., Miles, H., & Marley, J. (2002). Natural
history and familial relationships of infant spilling to 9 years of age. Pediatrics, 109(6), 1061–
7.
Martin, V., & Shaw-Smith, C. (2010). Review of genetic factors in intestinal malrotation.
Pediatric surgery international, 26(8), 769–81. doi:10.1007/s00383-010-2622-5
Merrill, A.E., Bochukova, E.G., Brugger, S.M., Ishii, M., Pilz, D.T., Wall, S.A, Lyons, K.M.,
Wilkie, A.O.M., & Maxson, R.E.Jr. (2006). Cell mixing at a neural crest-mesoderm boundary
and deficient ephrin-Eph signaling in the pathogenesis of craniosynostosis. Human molecular
genetics, 15(8), 1319–28. doi:10.1093/hmg/ddl052
Meyers, E.N., & Martin, G.R. (1999). Differences in left-right axis pathways in mouse and
chick: functions of FGF8 and SHH. Science (New York, N.Y.), 285(5426), 403–6.
Meyers, G.A., Day, D., Goldberg, R., Daentl, D.L., Przylepa, K.A., Abrams, L.J., Graham, J.M.,
Feingold, M., Moeschler, J.B., Rawnsley, E., Scott, A.F., & Jabs, E. W. (1996). FGFR2 Exon
Ilia and IlIc Mutations in Crouzon, Jackson-Weiss, and Pfeiffer Syndromes: Evidence for
47
Missense Changes, Insertions, and a Deletion Due to Alternative RNA Splicing. American
journal of human genetics, 58, 491–498.
Moayyedi, P., & Talley, N.J. (2006). Gastro-oesophageal reflux disease. The Lancet, 367(9528),
2086–2100.
Morriss-Kay, G.M., & Wilkie, A.O.M. (2005). Growth of the normal skull vault and its
alteration in craniosynostosis: insights from human genetics and experimental studies. Journal
of anatomy, 207(5), 637–53. doi:10.1111/j.1469-7580.2005.00475.x
Nagaraja, S., Anslow, P., & Winter, B. (2013). Craniosynostosis. Clinical radiology, 68(3), 284–
92. doi:10.1016/j.crad.2012.07.005
Nehra, D., & Goldstein, A.M. (2011). Intestinal malrotation: varied clinical presentation from
infancy through adulthood. Surgery, 149(3), 386–93. doi:10.1016/j.surg.2010.07.004
Neilson, K.M., & Friesel, R. (1996). Ligand-independent Activation of Fibroblast Growth Factor
Receptors by Point Mutations in the Extracellular, Transmembrane, and Kinase Domains.
Journal of Biological Chemistry, 271(40), 25049–25057. doi:10.1074/jbc.271.40.25049
Neugebauer, J.M., Amack, J.D., Peterson, A.G., Bisgrove, B.W., & Yost, H.J. (2009). FGF
signalling during embryo development regulates cilia length in diverse epithelia. Nature,
458(7238), 651–4. doi:10.1038/nature07753
Nonaka, S., Tanaka, Y., Okada, Y., Takeda, S., Harada, A., Kanai, Y., Kido, M., & Hirokawa, N.
(1998). Randomization of left-right asymmetry due to loss of nodal cilia generating leftward
flow of extraembryonic fluid in mice lacking KIF3B motor protein. Cell, 95(6), 829–37.
Ofodile, F., & Adeloye, A. (1982). Acrocephalyosyndactyly with hydrocephalus and
dextrocardia in a Nigerian child. Journal of The National Medical Association, 74(8), 800–
803.
Oldridge, M., Lunt, P.W., Zackai, E.H., McDonald-McGinn, D.M., Muenke, M., Moloney, D.
M., Twigg, S.R.F., Heath, J.K., Howard, T.D., Hoganson, G., Gagnon, D.M., Jabs, E.W., &
Wilkie, a O. (1997). Genotype-phenotype correlation for nucleotide substitutions in the IgII-
IgIII linker of FGFR2. Human molecular genetics, 6(1), 137–43.
48
Oliveira, N.A.J., Alonso, L.G., Fanganiello, R.D., & Passos-Bueno, M.R. (2006). Further
evidence of association between mutations in FGFR2 and syndromic craniosynostosis with
sacrococcygeal eversion. Birth defects research. Part A, Clinical and molecular teratology,
76(8), 629–33. doi:10.1002/bdra.20287
Ornitz, D.M., & Marie, P.J. (2002). FGF signaling pathways in endochondral and
intramembranous bone development and human genetic disease. Genes & development,
16(12), 1446–65. doi:10.1101/gad.990702
Park, W.J., Meyers, G.A., Li, X., Theda, C., Day, D., Orlow, S.J., Jones, M.C., & Jabs, E.W.
(1995). Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic
heterogeneity and phenotypic variability. Human molecular genetics, 4(7), 1229–33.
Passos-Bueno, M.R., Wilcox, W.R., Jabs, E.W., Sertié, A.L., Alonso, L.G., & Kitoh, H. (1999).
Clinical spectrum of fibroblast growth factor receptor mutations. Human mutation, 14(2),
115–25. doi:10.1002/(SICI)1098-1004(1999)14:2<115::AID-HUMU3>3.0.CO;2-2
Pickhardt, P.J., & Bhalla, S. (2002). Intestinal malrotation in adolescents and adults: spectrum of
clinical and imaging features. AJR. American journal of roentgenology, 179(6), 1429–35.
doi:10.2214/ajr.179.6.1791429
Plotnikov, A.N., Hubbard, S.R., Schlessinger, J., & Mohammadi, M. (2000). Crystal Structures
of Two FGF-FGFR Complexes Reveal the Determinants of Ligand-Receptor Specificity, 101,
413–424.
Ranger, A., Al-Hayek, A., & Matic, D. (2010). Chiari type 1 malformation in an infant with type
2 Pfeiffer syndrome: further evidence of acquired pathogenesis. The Journal of craniofacial
surgery, 21(2), 427–31. doi:10.1097/SCS.0b013e3181cfa792
Robin, N.H., Falk, M.J., & Haldeman-Englert, C.R. (2011). FGFR-Related Craniosynostosis
Syndromes. In R. Pagon, M. Adam, T. Bird, C. Dolan, C.-T. Fong, & K. Stephens (Eds.),
GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle.
Röttinger, E., Saudemont, A., Duboc, V., Besnardeau, L., McClay, D., & Lepage, T. (2008).
FGF signals guide migration of mesenchymal cells, control skeletal morphogenesis
49
[corrected] and regulate gastrulation during sea urchin development. Development
(Cambridge, England), 135(2), 353–65. doi:10.1242/dev.014282
Rousseau, F., Bonaventure, J., Legeai-Mallet, L., Pelet, A., Rozet, J.-M., Maroteaux, P., Le
Merrer, M., & Munnich, A. (1996). Mutations of the Fibroblast Growth Factor Receptor-3
Gene in Achondroplasia. Hormone Research in Paediatrics, 45(1-2), 108–110.
Schaefer, F., Anderson, C., Can, B., & Say, B. (1998). Novel mutation in the FGFR2 gene at the
same codon as the Crouzon syndrome mutations in a severe Pfeiffer syndrome type 2 case.
American journal of medical genetics, 75(3), 252–5.
Schlessinger, J., Plotnikov, A.N., Ibrahimi, O.A., Eliseenkova, A.V., Yeh, B.K., Yayon, A.,
Linhardt, R.J., & Mohammadi, M. (2000). Crystal structure of a ternary FGF-FGFR-heparin
complex reveals a dual role for heparin in FGFR binding and dimerization. Molecular cell,
6(3), 743–50.
Selber, J., Reid, R.R., Chike-Obi, C.J., Sutton, L.N., Zackai, E.H., McDonald-McGinn, D.,
Sonnad, S.S., Whitaker, L.A., Bartlett, S. P. (2008). The changing epidemiologic spectrum of
single-suture synostoses. Plastic and reconstructive surgery, 122(2), 527–33.
doi:10.1097/PRS.0b013e31817d548c
Sherman, P.M., Hassall, E., Fagundes-Neto, U., Gold, B. D., Kato, S., Koletzko, S., Orenstein,
S., Rudolph, C., Vakil, N., Vandenplas, Y. (2009). A global, evidence-based consensus on the
definition of gastroesophageal reflux disease in the pediatric population. The American
journal of gastroenterology, 104(5), 1278–95; quiz 1296. doi:10.1038/ajg.2009.129
Shiang, R., Thompson, L.M., Zhu, Y. Z., Church, D.M., Fielder, T.J., Bocian, M., Winokur, S.T.,
Wasmuth, J. J. (1994). Mutations in the transmembrane domain of FGFR3 cause the most
common genetic form of dwarfism, achondroplasia. Cell, 78(2), 335–42.
Slaney, S.F., Oldridge, M., Jane, A., Hall, C.M., Poole, M.D., & Morriss-kay, G.M. (1996).
Differential Effects of FGFR2 Mutations Palate in Apert Syndrome Syndactyly and Cleft,
923–932.
50
Slater, B.J., Lenton, K.A., Kwan, M.D., Gupta, D.M., Wan, D.C., & Longaker, M.T. (2008).
Cranial sutures: a brief review. Plastic and reconstructive surgery, 121(4), 170e–8e.
doi:10.1097/01.prs.0000304441.99483.97
Stevens, C.A., & Roeder, E.R. (2006). Ser351Cys mutation in the fibroblast growth factor
receptor 2 gene results in severe Pfeiffer syndrome. Clinical dysmorphology, 15(3), 187–8.
doi:10.1097/01.mcd.0000198930.32200.73
Strouse, P.J. (2004). Disorders of intestinal rotation and fixation (“malrotation”). Pediatric
radiology, 34(11), 837–51. doi:10.1007/s00247-004-1279-4
Szebenyi, G., & Fallon, J. F. (1999). Fibroblast growth factors as multifunctional signaling
factors. International review of cytology, 185, 45–106.
Tanaka, Y., Okada, Y., & Hirokawa, N. (2005). FGF-induced vesicular release of Sonic
hedgehog and retinoic acid in leftward nodal flow is critical for left-right determination.
Nature, 435(7039), 172–7. doi:10.1038/nature03494
Teebi, A.S., Kennedy, S., Chun, K., & Ray, P.N. (2002). Severe and Mild Phenotypes in Pfeiffer
Syndrome With Splice Acceptor Mutations in Exon IIIc of. American journal of medical
genetics, 107(September 2001), 43–47. doi:10.1002/ajmg.10125
Van den Brink, G.R. (2007). Hedgehog Signaling in Development and Homeostasis of the
Gastrointestinal Tract. Physiological Reviews, 1343–1375. doi:10.1152/physrev.00054.2006.
Van der Meulen, J., van der Hulst, R., van Adrichem, L., Arnaud, E., Chin-Shong, D., Duncan,
C., Habets, E., Hinojosa, J., Mathijssen, I., May, P., Morritt, D., Nishikawa, H., Noons, P.,
Richardson, D., Wall, S., van der Vlugt, J., Renier, D. (2009). The Increase of Metopic
Synostosis. Journal of Craniofacial Surgery, 20(2), 283–286.
doi:10.1097/SCS.0b013e31818436be
Weinzweig, J., Kirschner, R.E., Farley, A., Reiss, P., Hunter, J., Whitaker, L.A., & Bartlett, S.P.
(2003). Metopic synostosis: Defining the temporal sequence of normal suture fusion and
differentiating it from synostosis on the basis of computed tomography images. Plastic and
reconstructive surgery, 112(5), 1211–8. doi:10.1097/01.PRS.0000080729.28749.A3
51
Wilkie, A.O.M. (2001). Craniosynostosis , Genetics of, 478–481. doi:10.1006/rwgn.2001.1688
Wilkie, A.O.M. (2005). Bad bones, absent smell, selfish testes: the pleiotropic consequences of
human FGF receptor mutations. Cytokine & growth factor reviews, 16(2), 187–203.
doi:10.1016/j.cytogfr.2005.03.001
Wilkie, A.O.M., Byren, J.C., Hurst, J.A., Jayamohan, J., Johnson, D., Knight, S.J.L., Lester, T.,
Richards, P.G., Twigg, S.R.F., & Wall, S.A. (2010). Prevalence and complications of single-
gene and chromosomal disorders in craniosynostosis. Pediatrics, 126(2), e391–400.
doi:10.1542/peds.2009-3491
Wilkie, A.O.M., Slaney, S.F., Oldridge, M., Poole, M.D., Ashworth, G.J., Hockely, A.D.,
Hayward, R.D., David, D.J., Pulleyn, L.J., Rutland, P., Malcolm, S., Winter, R.M., &
Reardon, W. (1995). Apert syndrome results from localized mutation of FGFR2 and is allelic
with Crouzon syndrome. Nature Genetics, 9, 165–172.
Wolpert, L. (1996). One hundred years of positional information. Trends in genetics : TIG, 12(9),
359–64.
Xiao, L., Sobue, T., Esliger, A., Kronenberg, M.S., Coffin, J.D., Doetschman, T., & Hurley,
M.M. (2010). Disruption of the Fgf2 gene activates the adipogenic and suppresses the
osteogenic program in mesenchymal marrow stromal stem cells. Bone, 47(2), 360–70.
doi:10.1016/j.bone.2010.05.021
Zackai, E.H., McDonald-McGinn, D.M., Stolle, C., & Huff, D.S. (2003). Craniosynostosis with
tracheal sleeve: a patient with Pfeiffer syndrome, tracheal sleeve and additional malformations
in whom an FGFR2 mutation was found. Clinical dysmorphology, 12(3), 209.
doi:10.1097/01.mcd.0000080414.95344.ae
Zarate, Y.A, Putnam, P.E., & Saal, H.M. (2010). Intestinal malrotation in a patient with pfeiffer
syndrome type 2. The Cleft palate-craniofacial journal : official publication of the American
Cleft Palate-Craniofacial Association, 47(6), 638–41. doi:10.1597/09-115
52
IX. Appendices
Appendix A – Hospital for Sick Children Research Ethics Board Approval
53
Appendix B - The Hospital for Sick Children Research Ethics Board reapproval letter
54